The source of the conversation is Katherine's New York Times best seller - Bottle of Lies. From corporate malfeasance to efficacy of bioequivalence - this discussion covers a sweeping subject. This podcast has real relevance for health insurers, benefits advisors and employers who implement, manage and deliver drug insurance . The time for this conversation is past due. At the end of the day it's about the patients who rely on these drugs daily - either to sustain quality of life or perhaps even to sustain life. On any given day each of us is either a patient or could become one! Do we know how these dugs are manufactured, how they work and what goes into them?